Literature DB >> 28190601

Clinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancer.

Anne Ramlov1, Marianne S Assenholt2, Maria F Jensen2, Caroline Grønborg2, Remi Nout3, Markus Alber4, Lars Fokdal2, Kari Tanderup2, Jacob Chr Lindegaard2.   

Abstract

PURPOSE: To implement coverage probability (CovP) for dose planning of simultaneous integrated boost (SIB) of pathologic lymph nodes in locally advanced cervical cancer (LACC).
MATERIAL AND METHODS: CovP constraints for SIB of the pathological nodal target (PTV-N) with a central dose peak and a relaxed coverage at the perimeter were generated for use with the treatment planning system Eclipse: PTV-N D98 >90%, CTV-N D98 >100% and CTV-N D50 >101.5% of prescribed dose. Dose of EBRT was 45Gy/25 fx with a SIB of 55-57.5Gy depending on expected dose from brachytherapy (BT). Twenty-five previously treated patients with 47 boosted nodes were analysed. Nodes were contoured on cone beam CT (CBCT) and the accumulated dose in GTV-NCBCT and volume of body, pelvic bones and bowel receiving >50Gy (V50) were determined.
RESULTS: Nearly all nodes (89%) were visible on CBCT and showed considerable concentric regression during EBRT. Total EBRT and BT D98 was >57 GyEQD2 in 98% of the visible nodes. Compared to treatment plans aiming for full PTV-N coverage, CovP significantly reduced V50 of body, bones and bowel (p<0.001)
CONCLUSION: CovP is clinically feasible for SIB of pathological nodes and significantly decreases collateral SIB dose to nearby OAR.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Coverage probability; Nodal boosting; Radiotherapy

Mesh:

Year:  2017        PMID: 28190601     DOI: 10.1016/j.radonc.2017.01.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

Review 1.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Authors:  Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-11

2.  Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer.

Authors:  Daniel Wegener; Bernhard Berger; Zhoulika Outtagarts; Daniel Zips; Frank Paulsen; Martin Bleif; Daniela Thorwarth; Markus Alber; Oliver Dohm; Arndt-Christian Müller
Journal:  Radiol Oncol       Date:  2020-12-22       Impact factor: 2.991

3.  Robustness of elective lymph node target coverage with shrinking Planning Target Volume margins in external beam radiotherapy of locally advanced cervical cancer.

Authors:  Thomas Berger; Lars U Fokdal; Marianne S Assenholt; Nina B K Jensen; Jørgen B B Petersen; Lars Nyvang; Stine Korreman; Jacob C Lindegaard; Kari Tanderup
Journal:  Phys Imaging Radiat Oncol       Date:  2019-06-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.